CINECA IRIS Institutional Research Information System

FONTANINI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.043
AS - Asia 11.851
EU - Europa 8.574
SA - Sud America 1.972
AF - Africa 509
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 10
Totale 47.978
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.357
SG - Singapore 3.780
CN - Cina 3.383
HK - Hong Kong 2.304
IT - Italia 2.186
BR - Brasile 1.697
DE - Germania 1.520
SE - Svezia 1.214
BG - Bulgaria 899
GB - Regno Unito 658
VN - Vietnam 617
CA - Canada 561
TR - Turchia 549
UA - Ucraina 457
RU - Federazione Russa 439
FI - Finlandia 382
KR - Corea 334
IN - India 214
FR - Francia 194
CI - Costa d'Avorio 193
AT - Austria 157
CH - Svizzera 133
BD - Bangladesh 113
JP - Giappone 103
AR - Argentina 92
IQ - Iraq 87
SN - Senegal 81
ID - Indonesia 63
MX - Messico 63
PL - Polonia 61
BE - Belgio 60
NL - Olanda 56
ZA - Sudafrica 54
UZ - Uzbekistan 49
CO - Colombia 41
NG - Nigeria 41
EC - Ecuador 38
SA - Arabia Saudita 36
MA - Marocco 34
PK - Pakistan 34
ES - Italia 33
VE - Venezuela 33
JO - Giordania 23
PY - Paraguay 22
IL - Israele 20
AE - Emirati Arabi Uniti 19
EG - Egitto 19
KE - Kenya 19
AU - Australia 18
CZ - Repubblica Ceca 16
LT - Lituania 16
CL - Cile 15
AL - Albania 14
AZ - Azerbaigian 13
PE - Perù 13
TN - Tunisia 13
UY - Uruguay 12
DZ - Algeria 11
IE - Irlanda 11
BJ - Benin 10
NP - Nepal 10
RO - Romania 10
TH - Thailandia 10
DK - Danimarca 9
EU - Europa 9
TT - Trinidad e Tobago 9
JM - Giamaica 8
NI - Nicaragua 8
PT - Portogallo 8
AM - Armenia 7
BB - Barbados 7
CR - Costa Rica 7
MY - Malesia 7
ET - Etiopia 6
GE - Georgia 6
GR - Grecia 6
IR - Iran 6
KZ - Kazakistan 6
PH - Filippine 6
TW - Taiwan 6
AO - Angola 5
HU - Ungheria 5
LB - Libano 5
MD - Moldavia 5
OM - Oman 5
PA - Panama 5
BH - Bahrain 4
CG - Congo 4
DO - Repubblica Dominicana 4
EE - Estonia 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
BO - Bolivia 3
BS - Bahamas 3
GY - Guiana 3
HN - Honduras 3
Totale 47.915
Salva come PNG Salva come JPEG
Città #
Ashburn 2.627
Hong Kong 2.288
Fairfield 2.258
Woodbridge 2.132
Singapore 1.994
Chandler 1.741
Houston 1.596
Dallas 1.555
Ann Arbor 1.415
Santa Clara 1.271
Seattle 955
Sofia 897
Wilmington 852
Cambridge 798
Beijing 756
Shanghai 740
New York 574
Jacksonville 474
Ottawa 464
Boardman 453
Milan 401
Hefei 393
Princeton 391
Lawrence 364
Los Angeles 362
Izmir 328
Seoul 326
Medford 325
Nanjing 292
Des Moines 258
Serra 250
Pisa 227
Abidjan 193
Florence 183
Dong Ket 163
Istanbul 157
Dearborn 155
São Paulo 150
Buffalo 144
The Dalles 143
Columbus 140
Boulder 133
Redondo Beach 127
Bern 124
Vienna 123
San Diego 115
Munich 113
Frankfurt am Main 111
London 107
Council Bluffs 105
Nanchang 100
Ho Chi Minh City 99
Falls Church 89
Tokyo 85
Kunming 83
Bremen 82
Dakar 81
Ogden 79
Jüchen 70
Lancaster 68
Rio de Janeiro 63
Chicago 61
Brussels 55
Pune 53
Hanoi 52
Turku 52
Düsseldorf 50
Hebei 50
Shenyang 50
Warsaw 48
Redwood City 47
San Jose 45
Tashkent 45
Belo Horizonte 42
Changsha 41
Lagos 39
Jiaxing 38
Nuremberg 37
Phoenix 37
Fuzhou 36
Rome 36
Baghdad 34
Guangzhou 34
Toronto 31
Washington 31
Seacroft 30
Tianjin 30
Jakarta 29
San Francisco 29
Helsinki 26
Montreal 26
Norwalk 24
Nürnberg 24
Porto Alegre 24
Amman 23
Paris 23
Auburn Hills 22
Guarulhos 22
Hangzhou 22
Jinan 22
Totale 34.562
Salva come PNG Salva come JPEG
Nome #
null 346
La densità microvascolare (DMV) come marker prognostico e predittivo nelle neoplasie maligne dell'albero bronchiale in fase avanzata. 284
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 245
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 233
Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience 227
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 222
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 214
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 209
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 208
An atypical presentation of sporadic adult-onset centronuclear myopathy 204
Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med. 2002 Nov;10(5):589-92 202
Percutaneous radiofrequency ablation (pRTA) of pulmonary tumors 202
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance 201
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 197
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia 195
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center 192
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 190
Reply to P.M. Foye ( Letter ) 189
Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction 187
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 184
Second primary lung cancer and relapse: treatment and follow-up. 183
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments 182
Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features 182
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts 181
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. 181
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma 180
Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report 180
TERMOABLAZIONE DI NEOPLASIE POLMONARI MALIGNE: QUALI PROSPETTIVE 178
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 178
Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology? 177
FR-MLV INFECTION INDUCES ERYTHROLEUKEMIA INSTEAD OF LYMPHOID LEUKEMIA IN MICE GIVEN PITUITARY GRAFTS 176
A high vascular count and overexpression of Vascular Endothelial Growth Factor (VEGF) are associated with unfavorable prognosis in operated Small Cell Carcinoma (SCLC) 176
Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer 176
Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism 176
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 175
Screen-detected multiple primary lung cancers in the ITALUNG trial 175
Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma 173
Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy 173
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas 172
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study 171
Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. 171
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A 170
Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression 169
Alterations of Fas (APO-1/CD95) gene and its relationship with p53 in non small cell lung cancer 169
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial 169
CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma 167
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 167
Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer 166
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival? 166
2ND PRIMARY LUNG-CANCER AND RELAPSE - TREATMENT AND FOLLOW-UP 165
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 165
A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. 164
miR-19a and miR-20a and tissue factor expression in activated human peripheral blood mononuclear cells 164
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 163
Differential microRNA expression profiles between young and old lung adenocarcinoma patients. 163
KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung 162
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 161
Neoangiogenesis as prognostic indicator of survival in lung cancer. 160
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer 160
Accumulation of gene protein product P53 correlates with high microvessel count in non small cell lung carcinomas 159
Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice 159
Laparoscopic and thoracoscopic simultaneous resection of synchronous rectal and lung cancer 159
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 159
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 159
ANGIOGENIC POTENTIAL IN-VIVO BY KAPOSIS-SARCOMA CELL-FREE SUPERNATANTS AND HIV-1 TAT PRODUCT - INHIBITION OF KS-LIKE LESIONS BY TISSUE INHIBITOR OF METALLOPROTEINASE-2 158
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer 158
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). 158
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 158
Potentiation of the malignant phenotype of the undifferentiated aro thyroid cell line by insertion of the bcl-2 gene 157
Neoangiogenesis: A putative marker of malignancy in non-small-cell lung cancer (NSCLC) development 157
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 157
Evaluation of telomerase in non-melanoma skin cancer 156
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: A literature review 155
Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients 155
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 155
THE EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN IN PARAFFIN SECTIONS OF PERIPHERAL, NODE-NEGATIVE NON-SMALL-CELL LUNG-CANCER 154
LAPAROSCOPIC AND THORACHOSCOPIC SIMULATANEOUS RESECTION OF SYNCHRONOUS RECTAL AND LUNG CANCER 154
A preliminary study on radiofrequency thermal ablation of lung tumors 154
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients 154
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 151
Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction 151
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 150
Clear cell adenocarcinoma of the base of the tongue: a case report and review of the literature 150
The multimodality treatment of thymic carcinoma 150
Immunohistochemical and molecular study of radiation-induced multiple meningiomas with pleural and pulmonary metastasis 150
Expression Profiling of LKB1 Pathway in Young and Old Lung Adenocarcinoma Patients. 150
Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study. 149
Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations 149
VALUTAZIONE DELL'ATTIVITA' TELOMERASICA E DELL'ESPRESSIONE DI hTERT mRNA IN ADENOCARCINOMA DEL COLON 148
BLOOD-VESSEL INVASION BY TUMOR-CELLS PREDICTS RECURRENCE IN COMPLETELY RESECTED T1-N0-M0 NON-SMALL-CELL LUNG-CANCER 147
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 147
COINVOLGIMENTO DEL SISTEMA FAS(CD95/APO-1)/FAS LIGANDO NEL PROCESSO DI APOPTOSI p53-MEDIATO IN ADENOCARCINOMI DEL COLON 144
WWOX expression in different histologic types and subtypes of non-small cell lung cancer 144
The pathological and molecular diagnosis of malignant pleural mesothelioma: A literature review 144
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma 143
MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers 143
Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients 143
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 143
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 142
Totale 17.299
Salva come PNG Salva come JPEG
Categoria #
all - tutte 144.026
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 144.026
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.710 0 0 0 0 0 146 176 271 271 215 164 467
2021/20224.005 48 289 112 219 757 636 105 193 200 170 155 1.121
2022/20234.706 552 541 296 479 560 654 25 380 846 19 324 30
2023/20242.986 315 317 394 145 432 590 84 84 80 45 151 349
2024/202511.825 84 448 86 649 1.095 1.169 943 669 1.214 1.561 1.347 2.560
2025/20267.308 825 1.557 1.857 916 1.177 976 0 0 0 0 0 0
Totale 48.606